One dose of the Pfizer-BioNTech COVID-19 vaccine is sufficient in providing a robust immune response 11 days after inoculation against coronavirus.
COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.
‘The first Pfizer COVID-19 vaccine dose helped develop detectable neutralizing antibodies before the second dose.’
The findings, published as a preprint on the medRxiv* server, could help shape policy as vaccine rollout has been slow in countries such as the US and Canada. This could also increase with vaccine distribution efforts in developing countries where supplies have been scarce. For the study, the team re-examined Pfizer-BioNTech phase III trial data from day 1 to 111 in the placebo and experimental groups.
They also looked at data from Moderna's vaccine trial. However, since the number of Covid-19 cases in the Moderna trial was low in the first few weeks, they did not have sufficient data to assess it. Instead, Moderna's trial data was used for comparison purposes with Pfizer's trial data.
Pharma Companies Pfizer-BioNTech To Test Third Dose Of Covid Vaccine
Pfizer and BioNTech have started an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech Covid-19 vaccine (BNT162b2).
Pfizer and BioNTech have started an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech Covid-19 vaccine (BNT162b2).
While Moderna's sample size was limited, compared with the Pfizer-BioNTech's mRNA vaccine, there continued to be no significant difference in vaccine efficacy between days 11 to 35 and 7 days after the second vaccine was administered, the study indicated.
Advertisement
Covid Vaccine in 2021: Pfizer-BioNTech to Produce 2 Billion Doses
US-based pharma major Pfizer and a German pharmaceutical company BioNTech are gonna increase the manufacturing capacity to produce two billion doses of Covid-19 vaccine in this year, 2021.
US-based pharma major Pfizer and a German pharmaceutical company BioNTech are gonna increase the manufacturing capacity to produce two billion doses of Covid-19 vaccine in this year, 2021.
Pfizer's MRNA-Based Covid Vaccine Suspended
Over 23 Norwegian people who received Pfizer's mRNA-based Covid-19 vaccine died due to the vaccines' safety uncertainties. The new mRNA vaccine was developed in haste and had never been used on a large scale for the prevention of infectious disease.
Over 23 Norwegian people who received Pfizer's mRNA-based Covid-19 vaccine died due to the vaccines' safety uncertainties. The new mRNA vaccine was developed in haste and had never been used on a large scale for the prevention of infectious disease.
